文献速递哮喘

IL-17F而非IL-17A是激素不敏感型TDI诱导哮喘模型气道炎症的关键驱动因子

IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model.
PubMed 文献 · Eur Respir J · 2019-04-04

该研究在BALB/c小鼠TDI诱导哮喘模型中评估吸入和全身激素的效果,并探究IL-17A与IL-17F的功能。结果显示丙酸氟替卡松和泼尼松对气道高反应性、中性粒细胞和嗜酸性粒细胞增多及杯状细胞化生均无效;抗IL-17F改善气道高反应性和中性粒细胞增多,而抗IL-17A反而加重炎症。

要点

  • TDI诱导哮喘模型对吸入和全身激素均不敏感
  • 抗IL-17F可改善TDI诱导的气道高反应性和中性粒细胞增多
  • 抗IL-17A反而加重气道高反应性、黏液产生和嗜酸性粒细胞募集

核心结论

  • IL-17A和IL-17F在TDI诱导哮喘模型气道炎症中发挥不同的生物学效应。
  • 该模型对吸入和全身激素均无反应。

研究设计与样本

  • BALB/c小鼠暴露于TDI建立哮喘模型。
  • 小鼠接受吸入丙酸氟替卡松、全身泼尼松、抗IL-17A、抗IL-17F、重组IL-17A或IL-17F治疗。

主要发现

  • 丙酸氟替卡松和泼尼松对TDI诱导的气道高反应性、支气管中性粒细胞和嗜酸性粒细胞增多及上皮杯状细胞化生均无效果。
  • 丙酸氟替卡松或泼尼松未抑制TDI诱导的Th2和Th17特征。
  • TDI暴露后抗IL-17A治疗导致气道高反应性增加、黏液产生加重和气道嗜酸性粒细胞募集,伴随Th2反应增强。
  • 抗IL-17F改善TDI诱导的气道高反应性和气道中性粒细胞增多,伴随Th17反应降低。
  • 重组IL-17A和IL-17F显示出与单克隆抗体相反的效果。

临床怎么用

  • 在激素不敏感的TDI诱导哮喘中,靶向IL-17F而非IL-17A可能是有前景的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Steroid insensitivity constitutes a major problem for asthma management. Toluene diisocyanate (TDI) is one of the leading allergens of asthma that induces both T-helper Th2 and Th17 responses, and is often associated with poor responsiveness to steroid treatment in the clinic.We sought to evaluate the effects of inhaled and systemic steroids on a TDI-induced asthma model and to find how interleukin (IL)-17A and IL-17F function in this model. BALB/c mice were exposed to TDI for generating an asthma model and were treated with inhaled fluticasone propionate, systemic prednisone, anti-IL-17A, anti-IL-17F, recombinant IL-17A or IL-17F.Both fluticasone propionate and prednisone showed no effects on TDI-induced airway hyperresponsiveness (AHR), bronchial neutrophilia and eosinophilia, and epithelial goblet cell metaplasia. TDI-induced Th2 and Th17 signatures were not suppressed by fluticasone propionate or prednisone. Treatment with anti-IL-17A after TDI exposure led to increased AHR, aggravated mucus production and airway eosinophil recruitment, accompanied by amplified Th2 responses, whereas anti-IL-17F ameliorated TDI-induced AHR and airway neutrophilia, with decreased Th17 responses. Recombinant IL-17A and IL-17F showed opposite effects to the monoclonal antibodies.IL-17A and IL-17F exert distinct biological effects during airway inflammation of a TDI-induced asthma model, which is unresponsive to both inhaled and systemic steroids.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Chen R, Zhang Q, Chen S, et al. IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model. Eur Respir J. 2019. PMID: 30655284. doi:10.1183/13993003.01510-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。